

Health Care/Finland, October 30, 2019
Preview

Towards profitability improvement

Pihlajalinna will report its Q3 earnings on next week's Tuesday, 5th of November. Our interest is on how the execution of the efficiency improvement program is going and what are the impacts for Q3. We have increased our revenue and earnings estimates by 1–2%, resulting from the cooperation agreement with Pohjola Insurance. We keep our rating "BUY" with TP of EUR 12 ahead of Q3.

Changes in service network


Pihlajalinna has faced efficiency problems especially with the new clinics which has impacted negatively on the company's profitability. In order to improve profitability, the company launched an efficiency improvement program in H1 that aims to achieve annual cost savings of EUR 17m. The planned cost savings are expected to be realized during 2020. As a result of the efficiency improvement program the company informed that it will merge units but closures of some of the loss-making clinics are also possible. We have already seen some actions taken during Q3 as the company has announced changes (mergers and unit closures) to its service network at least in Eastern and Southwest Finland.

Cooperation agreement with Pohjola Insurance

Pihlajalinna and Pohjola Insurance signed a cooperation agreement in early September which is a continuation to the successful pilot project that took place during the summer. The company estimates that the turnover from the contract could be some EUR 5-10m per annum, which means 1-2% increase in revenue. As a result of the agreement we have increased our revenue and earnings estimates by 1-2% for 2020E-2021E.

We retain "BUY" with TP of EUR 12

We expect Q3'19E revenue to grow by 5.8% to EUR 123m (cons. of EUR 122m) driven by new clinics and fitness centers. We expect adj. EBIT of EUR 6.8m (cons. of EUR 5.4m) resulting in EBIT margin of 5.6%. We expect profitability to improve from last year as some of the costs savings are expected to be shown already in Q3'19. We keep our rating "BUY" with TP of EUR 12.



Share price, EUR (Last trading day's closing price)	10.50
Target price, EUR	12.0
Latest change in rating	02-Nov-18
Latest report on company	16-Aug-19
Research paid by issuer:	YES
No. of shares outstanding,	22,620
No. of shares fully diluted,	22,620
Market cap, EURm	238
Free float, %	57.0
Exchange rate	0.000
Reuters code	PIHLIS.HE
Bloomberg code	PIHLIS FH
Average daily volume, EURm	na.
Next interim report	05-Nov-19
Web site	http://investors.pihlajalinna.fi/
Analyst	Anna-Liisa Rissanen
E-mail	annaliisa.rissanen@evli.com
Telephone	+358401579919

■ BUY □ HOLD ■ SELL

KEY FIGU	RES									
	Sales EURm	EBIT EURm	EBIT %	FCF EURm	EPS EUR	P/E (x)	EV/Sales (x)	EV/EBIT (x)	FCF yield %	DPS EUR
2017	424.0	20.1	4.7%	-9.5	0.52	25.7	0.8	16.2	-3.5	0.16
2018	487.8	14.4	3.0%	-48.0	0.20	42.4	0.8	27.1	-24.6	0.10
2019E	518.0	20.5	4.0%	2.1	0.49	21.5	0.8	21.2	0.9	0.16
2020E	533.6	34.0	6.4%	12.3	0.94	11.2	0.8	12.5	5.2	0.31
2021E	546.9	36.6	6.7%	24.7	1.03	10.2	0.7	11.1	10.4	0.34
Market cap	o, EURm		238 G	earing 2019E,	0/0		1, %	71.8		
Net debt 2	019E, EURm		181 P	rice/book 2019	ÐΕ		1.8 CAGR	sales 2018-	21, %	3.9
Enterprise	value, EURm		435 D	ividend yield 2	2019E, %		1.5 ROE 2	019E, %		8.8
Total asset	s 2019E, EURn	n	441 Ta	ax rate 2019E,	0/0		21.3 ROCE	2019E, %		5.8
Goodwill 2	019E, EURm		170 E	quity ratio 201	9E, %		31.6 PEG, F	P/E 19/CAGR		0.7

All the important disclosures can be found on the last pages of this report.

Health Care/Finland, October 30, 2019 Preview

Estimates

Net sales	2017	Q1'18	Q2'18	Q3'18	Q4'18	2018E	Q1'19	Q2'19	Q3'19E	Q4'19E	2019E	2020E
Corporate Customers	82.6	26.2	25.3	22.8	29.4	103.7	31.6	30.3	27.2	33.1	122.1	131.7
of which insurance companies	26.6	6.6	6.6	5.3	6.7	25.2	7.1	6.7	7.3	7.9	29.0	36.8
of which other corporates	56.0	19.6	18.7	17.5	22.7	78.5	24.5	23.6	19.9	25.2	93.1	95.0
Private Customers	67.9	22.2	24.3	21.0	24.6	92.1	26.5	25.6	22.0	25.4	99.5	99.5
Public sector customers	330.5	85.1	90.3	85.7	88.6	349.7	89.3	89.6	87.5	90.3	356.6	363.8
Total	424.0	119.3	125.3	116.3	126.9	487.8	132.5	129.7	123.0	132.7	518.0	533.6
Net sales growth												
Corporate Customers	-	17.0%	21.1%	25.3%	39.3%	25.5%	20.6%	19.6%	19.1%	12.4%	17.7%	7.9%
Private Customers	-	16.8%	35.0%	54.4%	42.2%	35.6%	19.4%	5.1%	4.9%	3.2%	8.0%	0.0%
Public sector customers	-	2.5%	9.9%	6.1%	4.9%	5.8%	4.9%	-0.8%	2.1%	1.9%	2.0%	2.0%
Total	6.2%	8.5%	17.5%	17.0%	17.5%	15.0%	11.1%	3.5%	5.8%	4.6%	6.2%	3.0%
Adj. EBITDA (group)	34.0	6.9	10.2	14.2	14.6	45.9	12.6	10.8	15.7	16.6	55.7	66.2
Adj. EBITDA-margin (group)	8.0%	5.8%	8.1%	12.2%	11.5%	9.4%	9.5%	8.3%	12.8%	12.5%	10.8%	12.4%

Source: Pihlajalinna, Evli Research

Valuation

	Security	MCAP	EV/EBITDA	EV/EBITDA	EV/EBITDA	EV/EBIT	EV/EBIT	EV/EBIT	P/E	P/E	P/E
PIHLAJALINNA PEER GROUP	identifier	Local FX	19	20	21	19	20	21	19	20	21
Ambea AB	AMBEA-SE	6822	10,6x	8,4x	7,5x	23,0x	17,1x	14,6x	14,8x	12,8x	10,9x
Attendo AB	ATT-SE	7838	11,3x	10,3x	9,3x	32,0x	28,5x	23,2x	55,1x	36,3x	23,6x
CareTech Holdings PLC	CTH-GB	428	10,1x	8,8x	7,9x	12,2x	10,4x	9,4x	11,1x	9,2x	8,0x
Fresenius SE & Co. KGaA	FRE-DE	25307	6,6x	6,0x	5,5x	9,6x	8,7x	7,9x	13,8x	12,9x	12,0x
Georgia Healthcare Group Plc	GHG-GB	107	7,7x	6,4x	5,2x	10,0x	7,9x	6,4x	19,3x	13,2x	10,2x
GHP Specialty Care AB	GHP-SE	1212	8,5x	7,4x	6,5x	18,4x	14,7x	13,0x	27,3x	22,2x	19,7x
Humana AB	HUM-SE	3114	9,1x	7,8x	7,2x	16,4x	13,6x	12,5x	14,2x	11,3x	10,4x
Korian SA	KORI-FR	3127	12,4x	11,5x	11,4x	18,8x	17,2x	16,9x	23,0x	19,5x	16,7x
LNA Sante SA	LNA-FR	454	11,4x	10,3x	9,2x	15,4x	13,8x	12,6x	19,1x	16,6x	14,6x
Mediclinic International Plc	MDC-GB	2760	8,5x	7,9x	7,4x	13,2x	12,2x	11,2x	14,5x	13,1x	11,5x
Orpea SA	ORP-FR	6845	19,4x	17,9x	16,8x	26,6x	24,6x	23,1x	27,4x	24,3x	21,8x
RHON-KLINIKUM AG	RHK-DE	1257	10,3x	9,9x	9,5x	26,9x	25,3x	23,6x	40,1x	36,9x	34,2x
Spire Healthcare Group PLC	SPI-GB	473	7,4x	6,8x	6,7x	15,4x	13,8x	13,3x	23,2x	18,1x	14,0x
Terveystalo Oy Class A	TTALO-FI	1239	10,9x	9,9x	9,1x	19,7x	17,3x	15,8x	22,7x	19,4x	16,7x
Peer Group Median		4410	10,2x	8,6x	7,7x	17,4x	14,3x	13,1x	21,0x	17,3x	14,3x
Peer Group Average		2009	10,3x	9,2x	8,5x	18,4x	16,1x	14,5x	23,3x	19,0x	16,0x
Pihlajalinna (Evli est.)		238	7,8x	6,4x	5,7x	21,2x	12,5x	11,1x	21,5x	11,2x	10,2x
5011.0				0 = 0/			4001			0 = 01	

Pihlajalinna premium/discount to peer median

Source: Factset, Evli Research

Health Care/Finland, October 30, 2019 Preview

INTERIM FIGURES

Net sales	EVLI ESTIMATES, EURm	2018Q1	2018Q2	2018Q3	2018Q4	2018	2019Q1	2019Q2	2019Q3E	2019Q4E	2019E	2020E	2021E
EBITDA 6.9 10.1 13.8 15.1 45.9 12.5 10.8 15.7 16.6 55.7 66.2 70.9 EBITDA 5.8 8.1 11.9 11.9 9.4 9.4 8.4 12.8 12.5 10.7 12.4 13.0 EBIT													
EBITDA margin (%) 5.8 8.1 11.9 11.9 9.4 9.4 8.4 12.8 12.5 10.7 12.4 13.0 (BBIT argin (%)) -0.1 2.0 5.6 6.9 14.4 3.9 2.1 6.8 7.7 20.5 34.0 36.6 (BBIT margin (%)) -0.1 1.6 4.8 5.4 3.0 2.9 1.6 5.6 5.6 5.8 4.0 6.4 6.7 (Net financial items) -1.0 -0.8 -0.9 -1.1 -3.8 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 4.0 5.0 5.5 (Net financial items) -1.1 1.2 4.7 5.8 10.6 2.9 1.1 5.8 6.7 16.5 29.0 31.6 (Sax argin (%)) -1.1 1.2 4.7 5.8 10.6 2.9 1.1 5.8 6.7 16.5 29.0 31.6 (Sax argin (%)) -1.2 4.7 5.8 10.6 2.9 1.1 5.8 6.7 16.5 29.0 31.6 (Sax argin (%)) -1.2 4.7 1.0 1.3 -2.7 -0.7 -0.7 -0.3 -1.2 -1.3 -3.5 5.8 6.3 13.6 (Sax argin (%)) -1.2 4.7 1.0 1.9 3.4 4.6 1.8 -0.1 4.4 5.0 11.1 21.2 23.3 (Sax argin (%)) -1.2 5.8 5.8 5.8 5.8 5.8 5.8 5.8 5.8 5.8 5.8													
EBIT0.1 2.0 5.6 6.9 14.4 3.9 2.1 6.8 7.7 20.5 34.0 36.6 EBIT margin (%) -0.7 1.6 4.8 5.4 3.0 2.9 1.6 5.6 5.8 4.0 6.4 6.7 6.5					-								13.0
EBIT margin (%) -0.1 1.6 4.8 5.4 3.0 2.9 1.6 5.6 5.8 4.0 6.4 6.7 Net financial items -1.0 -0.8 -0.9 -1.1 -3.8 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -4.0 -5.0 -5.0 Fer-tax profit -1.1 1.2 4.7 5.8 10.6 2.9 1.1 5.8 6.7 16.5 2.9 31.6 Tax 0.0 -0.3 -1.1 -1.3 -2.7 -0.7 -0.3 -1.2 -1.3 -3.5 -5.8 -6.3 Tax rate (%) 0.0 2.5.0 23.4 22.4 25.5 24.1 28.6 20.0 20.0 21.3 20.0 20.0 Net profit -1.7 1.0 1.9 3.4 4.6 1.8 -0.1 4.4 5.0 11.1 21.2 23.3 EPS 40.0 4.0 0.8 0.15 0.20 0.08 -0.01 0.19 0.22 0.49 0.94 1.03 Dividend per share 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.	EBIT	-0.1	2.0	5.6	6.9	14.4	3.9	2.1	6.8		20.5	34.0	36.6
Net financial items	EBIT margin (%)	-0.1	1.6	4.8			2.9		5.6	5.8	4.0	6.4	6.7
Tax	Net financial items	-1.0	-0.8	-0.9	-1.1	-3.8	-1.0	-1.0	-1.0	-1.0	-4.0	-5.0	-5.0
Tax rate (%) 0.0 25.0 23.4 22.4 25.5 24.1 28.6 20.0 20.0 21.3 20.0 20.0 Net profit -1.7 1.0 1.9 3.4 4.6 1.8 -0.1 4.4 5.0 11.1 21.2 23.3 EPS -0.08 0.04 0.08 0.15 0.20 0.08 -0.01 0.19 0.22 0.49 0.94 1.03 EPS adjusted (diluted no. of shares) -0.08 0.04 0.08 0.15 0.20 0.08 -0.01 0.19 0.22 0.49 0.94 1.03 Dividend per share 0.00	Pre-tax profit	-1.1	1.2	4.7	5.8	10.6	2.9	1.1	5.8	6.7	16.5	29.0	31.6
Net profit -1.7 1.0 1.9 3.4 4.6 1.8 -0.1 4.4 5.0 11.1 21.2 23.3 EPS -0.08 0.04 0.08 0.15 0.20 0.08 -0.01 0.19 0.22 0.49 0.94 1.03 EPS adjusted (diluted no. of shares) -0.08 0.04 0.08 0.15 0.20 0.08 -0.01 0.19 0.22 0.49 0.94 1.03 Dividend per share -0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	Tax	0.0	-0.3	-1.1	-1.3	-2.7	-0.7	-0.3	-1.2	-1.3	-3.5	-5.8	-6.3
EPS -0.08 0.04 0.08 0.15 0.20 0.08 -0.01 0.19 0.22 0.49 0.94 1.03 EPS adjusted (diluted no. of shares) -0.08 0.04 0.08 0.15 0.20 0.08 -0.01 0.19 0.22 0.49 0.94 1.03 Dividend per share 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.	Tax rate (%)	0.0	25.0	23.4	22.4	25.5	24.1	28.6	20.0	20.0	21.3	20.0	20.0
EPS adjusted (diluted no. of shares)	Net profit	-1.7	1.0	1.9	3.4	4.6	1.8	-0.1	4.4	5.0	11.1	21.2	23.3
Dividend per share 0.00	EPS	-0.08	0.04	0.08	0.15	0.20	0.08	-0.01	0.19	0.22	0.49	0.94	1.03
SALES, EURm Corporate Customers 27.7 23.8 24.8 29.4 105.7 31.6 30.3 27.2 33.1 122.1 131.7 135.0 Private Customers 22.2 24.3 20.9 24.6 92.0 26.5 25.6 22.0 25.4 99.5 99.5 101.9 Public sector customers 83.5 91.9 83.7 88.6 347.7 89.3 89.6 87.5 90.3 356.6 363.8 372.9 Eliminations -14.2 -14.7 -13.1 -15.6 -57.6 -14.9 -15.7 -13.6 -16.0 -60.2 -61.4 -62.9 Total 119.2 125.3 116.3 127.0 487.8 132.5 129.7 123.0 132.7 518.0 533.6 546.9 SALES GROWTH, Y/Y % Corporate Customers 23.7 13.9 36.3 39.3 28.0 14.1 27.1 9.5 12.4 15.5 7.9 2.5 Public sector customers 23.7 13.9 36.3 39.3 28.0 14.1 27.1 <td< td=""><td>EPS adjusted (diluted no. of shares)</td><td>-0.08</td><td>0.04</td><td>0.08</td><td>0.15</td><td>0.20</td><td>0.08</td><td>-0.01</td><td>0.19</td><td>0.22</td><td>0.49</td><td>0.94</td><td>1.03</td></td<>	EPS adjusted (diluted no. of shares)	-0.08	0.04	0.08	0.15	0.20	0.08	-0.01	0.19	0.22	0.49	0.94	1.03
Corporate Customers 27.7 23.8 24.8 29.4 105.7 31.6 30.3 27.2 33.1 122.1 131.7 135.0 Private Customers 22.2 24.3 20.9 24.6 92.0 26.5 25.6 22.0 25.4 99.5 99.5 101.9 Public sector customers 83.5 91.9 83.7 88.6 347.7 89.3 89.6 87.5 90.3 356.6 363.8 372.9 Eliminations -14.2 -14.7 -13.1 -15.6 -57.6 -14.9 -15.7 -13.6 -16.0 -60.2 -61.4 -62.9 Total 119.2 125.3 116.3 127.0 487.8 132.5 129.7 123.0 132.7 518.0 533.6 546.9 SALES GROWTH, Y/Y % 23.7 13.9 36.3 39.3 28.0 14.1 27.1 9.5 12.4 15.5 7.9 2.5 Private Customers 16.8 35.0 53.7	Dividend per share	0.00	0.00	0.00	0.00	0.10	0.00	0.00	0.00	0.00	0.16	0.31	0.34
Private Customers 22.2 24.3 20.9 24.6 92.0 26.5 25.6 22.0 25.4 99.5 99.5 101.9 Public sector customers 83.5 91.9 83.7 88.6 347.7 89.3 89.6 87.5 90.3 356.6 363.8 372.9 Eliminations -14.2 -14.7 -13.1 -15.6 -57.6 -14.9 -15.7 -13.6 -16.0 -60.2 -61.4 -62.9 Total 119.2 125.3 116.3 127.0 487.8 132.5 129.7 123.0 132.7 518.0 533.6 546.9 SALES GROWTH, Y/Y %	SALES, EURm												
Public sector customers 83.5 91.9 83.7 88.6 347.7 89.3 89.6 87.5 90.3 356.6 363.8 372.9 Eliminations -14.2 -14.7 -13.1 -15.6 -57.6 -14.9 -15.7 -13.6 -16.0 -60.2 -61.4 -62.9 Total 119.2 125.3 116.3 127.0 487.8 132.5 129.7 123.0 132.7 518.0 533.6 546.9 SALES GROWTH, Y/Y %	Corporate Customers	27.7	23.8	24.8	29.4	105.7	31.6	30.3	27.2	33.1	122.1	131.7	135.0
Eliminations -14.2 -14.7 -13.1 -15.6 -57.6 -14.9 -15.7 -13.6 -16.0 -60.2 -61.4 -62.9 Total 119.2 125.3 116.3 127.0 487.8 132.5 129.7 123.0 132.7 518.0 533.6 546.9 SALES GROWTH, Y/Y % Corporate Customers 23.7 13.9 36.3 39.3 28.0 14.1 27.1 9.5 12.4 15.5 7.9 2.5 Private Customers 16.8 35.0 53.7 42.2 35.5 19.4 5.1 5.4 3.2 8.1 0.0 2.5 Public sector customers 0.6 11.8 3.6 4.9 5.2 6.9 -2.5 4.5 1.9 2.6 2.0 2.5 Eliminations -1.4 1.4 -0.8 4.7 1.1 4.9 6.8 3.8 2.7 4.5 2.0 2.5 Total 8.4 17.5 17.0 17.6 15.0 11.2 3.5 5.8 4.5 6.2 3.0 2.5 EBIT, EURM Group -0.1 2.0 5.6 6.9 14.4 3.9 2.1 6.8 7.7 20.5 34.0 36.6 EBIT margin, %	Private Customers	22.2	24.3	20.9	24.6	92.0	26.5	25.6	22.0	25.4	99.5	99.5	101.9
Total 119.2 125.3 116.3 127.0 487.8 132.5 129.7 123.0 132.7 518.0 533.6 546.9 SALES GROWTH, Y/Y % Corporate Customers 23.7 13.9 36.3 39.3 28.0 14.1 27.1 9.5 12.4 15.5 7.9 2.5 Private Customers 16.8 35.0 53.7 42.2 35.5 19.4 5.1 5.4 3.2 8.1 0.0 2.5 Public sector customers 0.6 11.8 3.6 4.9 5.2 6.9 -2.5 4.5 1.9 2.6 2.0 2.5 Eliminations -1.4 1.4 -0.8 4.7 1.1 4.9 6.8 3.8 2.7 4.5 2.0 2.5 Total 8.4 17.5 17.0 17.6 15.0 11.2 3.5 5.8 4.5 6.2 3.0 2.5 EBIT, EURM Group -0.1 2.0 5.6 6.9 14.4 3.9 2.1 6.8 7.7 20.5 34.0 36.6 EBIT margin, %	Public sector customers	83.5	91.9	83.7	88.6	347.7	89.3	89.6	87.5	90.3	356.6	363.8	372.9
SALES GROWTH, Y/Y % Corporate Customers 23.7 13.9 36.3 39.3 28.0 14.1 27.1 9.5 12.4 15.5 7.9 2.5 Private Customers 16.8 35.0 53.7 42.2 35.5 19.4 5.1 5.4 3.2 8.1 0.0 2.5 Public sector customers 0.6 11.8 3.6 4.9 5.2 6.9 -2.5 4.5 1.9 2.6 2.0 2.5 Eliminations -1.4 1.4 -0.8 4.7 1.1 4.9 6.8 3.8 2.7 4.5 2.0 2.5 Total 8.4 17.5 17.0 17.6 15.0 11.2 3.5 5.8 4.5 6.2 3.0 2.5 EBIT, EURm Group -0.1 2.0 5.6 6.9 14.4 3.9 2.1 6.8 7.7 20.5 34.0 36.6 Total -0.1 2.0 5.6 6.9 14.4 3.9 2.1 6.8 7.7 20.5 34	Eliminations	-14.2	-14.7	-13.1	-15.6	-57.6	-14.9	-15.7	-13.6	-16.0	-60.2	-61.4	-62.9
Corporate Customers 23.7 13.9 36.3 39.3 28.0 14.1 27.1 9.5 12.4 15.5 7.9 2.5 Private Customers 16.8 35.0 53.7 42.2 35.5 19.4 5.1 5.4 3.2 8.1 0.0 2.5 Public sector customers 0.6 11.8 3.6 4.9 5.2 6.9 -2.5 4.5 1.9 2.6 2.0 2.5 Eliminations -1.4 1.4 -0.8 4.7 1.1 4.9 6.8 3.8 2.7 4.5 2.0 2.5 Total 8.4 17.5 17.0 17.6 15.0 11.2 3.5 5.8 4.5 6.2 3.0 2.5 EBIT, EURm 5.6 6.9 14.4 3.9 2.1 6.8 7.7 20.5 34.0 36.6 Total -0.1 2.0 5.6 6.9 14.4 3.9 2.1 6.8 7.7 20.	Total	119.2	125.3	116.3	127.0	487.8	132.5	129.7	123.0	132.7	518.0	533.6	546.9
Private Customers 16.8 35.0 53.7 42.2 35.5 19.4 5.1 5.4 3.2 8.1 0.0 2.5 Public sector customers 0.6 11.8 3.6 4.9 5.2 6.9 -2.5 4.5 1.9 2.6 2.0 2.5 Eliminations -1.4 1.4 -0.8 4.7 1.1 4.9 6.8 3.8 2.7 4.5 2.0 2.5 Total 8.4 17.5 17.0 17.6 15.0 11.2 3.5 5.8 4.5 6.2 3.0 2.5 EBIT, EURm Group -0.1 2.0 5.6 6.9 14.4 3.9 2.1 6.8 7.7 20.5 34.0 36.6 Total -0.1 2.0 5.6 6.9 14.4 3.9 2.1 6.8 7.7 20.5 34.0 36.6 EBIT margin, % -0.1 2.0 5.6 6.9 14.4 3.9 2.1 6.8 7.7 20.5 34.0 36.6	SALES GROWTH, Y/Y %												
Public sector customers 0.6 11.8 3.6 4.9 5.2 6.9 -2.5 4.5 1.9 2.6 2.0 2.5 Eliminations -1.4 1.4 -0.8 4.7 1.1 4.9 6.8 3.8 2.7 4.5 2.0 2.5 Total 8.4 17.5 17.0 17.6 15.0 11.2 3.5 5.8 4.5 6.2 3.0 2.5 EBIT, EURm Group -0.1 2.0 5.6 6.9 14.4 3.9 2.1 6.8 7.7 20.5 34.0 36.6 Total -0.1 2.0 5.6 6.9 14.4 3.9 2.1 6.8 7.7 20.5 34.0 36.6 EBIT margin, %	Corporate Customers	23.7	13.9	36.3	39.3	28.0	14.1	27.1	9.5	12.4	15.5	7.9	2.5
Eliminations -1.4 1.4 -0.8 4.7 1.1 4.9 6.8 3.8 2.7 4.5 2.0 2.5 Total 8.4 17.5 17.0 17.6 15.0 11.2 3.5 5.8 4.5 6.2 3.0 2.5 EBIT, EURm Group -0.1 2.0 5.6 6.9 14.4 3.9 2.1 6.8 7.7 20.5 34.0 36.6 Total -0.1 2.0 5.6 6.9 14.4 3.9 2.1 6.8 7.7 20.5 34.0 36.6 EBIT margin, % 8 2.7 2.5 34.0 36.6	Private Customers	16.8	35.0	<i>53.7</i>	42.2	35.5	19.4	5.1	5.4	3.2	8.1	0.0	2.5
Total 8.4 17.5 17.0 17.6 15.0 11.2 3.5 5.8 4.5 6.2 3.0 2.5 EBIT, EURm Group -0.1 2.0 5.6 6.9 14.4 3.9 2.1 6.8 7.7 20.5 34.0 36.6 Total -0.1 2.0 5.6 6.9 14.4 3.9 2.1 6.8 7.7 20.5 34.0 36.6 EBIT margin, %	Public sector customers	0.6	11.8	3.6	4.9	5.2	6.9	-2.5	4.5	1.9	2.6	2.0	2.5
EBIT, EURm Coroup -0.1 2.0 5.6 6.9 14.4 3.9 2.1 6.8 7.7 20.5 34.0 36.6 Total -0.1 2.0 5.6 6.9 14.4 3.9 2.1 6.8 7.7 20.5 34.0 36.6 EBIT margin, % EBIT margin, %	Eliminations	-1.4	1.4	-0.8	4.7	1.1	4.9	6.8	3.8	2.7	4.5	2.0	2.5
Group -0.1 2.0 5.6 6.9 14.4 3.9 2.1 6.8 7.7 20.5 34.0 36.6 Total -0.1 2.0 5.6 6.9 14.4 3.9 2.1 6.8 7.7 20.5 34.0 36.6 EBIT margin, %	Total	8.4	17.5	17.0	17.6	15.0	11.2	3.5	5.8	4.5	6.2	3.0	2.5
Total -0.1 2.0 5.6 6.9 14.4 3.9 2.1 6.8 7.7 20.5 34.0 36.6 EBIT margin, %	EBIT, EURm												
EBIT margin, %	Group	-0.1	2.0	5.6	6.9	14.4	3.9	2.1	6.8	7.7	20.5	34.0	36.6
	Total	-0.1	2.0	5.6	6.9	14.4	3.9	2.1	6.8	7.7	20.5	34.0	36.6
Total -0.1 1.6 4.8 5.4 3.0 2.9 1.6 5.6 5.8 4.0 6.4 6.7	EBIT margin, %												
	Total	-0.1	1.6	4.8	5.4	3.0	2.9	1.6	5.6	5.8	4.0	6.4	6.7

Health Care/Finland, October 30, 2019 Preview

INCOME STATEMENT, EURm	2014	2015	2016	2017	2018	2019E	2020E	2021E
Sales	148.9	213.4	399.1	424.0	487.8	518.0	533.6	546.9
Sales growth (%)	42.6	43.3	87.0	6.2	15.0	6.2	3.0	2.5
EBITDA	13.8	12.7	29.4	34.3	45.9	55.7	66.2	70.9
EBITDA margin (%)	9.3	6.0	7.4	8.1	9.4	10.7	12.4	13.0
Depreciation	-5.8	-8.0	-12.8	-14.2	-31.5	-20.4	-19.0	-20.4
EBITA	8.0	4.7	16.6	20.1	14.4	20.5	34.0	36.6
Goodwill amortization / writedown	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	8.0	4.7	16.6	20.1	14.4	20.5	34.0	36.6
EBIT margin (%)	5.4	2.2	4.2	4.7	3.0	4.0	6.4	6.7
Reported EBIT	5.9	3.9	15.1	19.2	13.8	20.5	34.0	36.6
EBIT margin (reported) (%)	4.0	1.8	3.8	4.5	2.8	4.0	6.4	6.7
Net financials	-3.1	-2.3	-1.2	-1.4	-3.8	-4.0	-5.0	-5.0
Pre-tax profit	4.9	2.4	15.4	18.7	10.6	16.5	29.0	31.6
Taxes	-1.0	-0.1	-3.0	-3.4	-2.7	-3.5	-5.8	-6.3
Minority shares	-0.4	-0.8	-2.7	-4.6	-3.3	-1.9	-2.0	-2.0
Net profit	1.4	0.7	8.2	9.8	4.0	11.1	21.2	23.3
Cash NRIs	-2.1	-0.8	-1.5	-0.9	-0.6	0.0	0.0	0.0
Non-cash NRIs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
BALANCE SHEET, EURm								
Assets								
Fixed assets	47	69	67	83	68	79	83	80
Goodwill	56	76	92	104	170	170	170	170
Right of use assets	0	0	0	0	116	117	123	126
Inventory	1	2	2	2	3	3	3	3
Receivables	14	20	27	25	40	33	34	35
Liquid funds	11	15	28	37	36	36	37	38
Total assets	131	185	218	254	437	441	454	455
Liabilities								
Shareholder's equity	9	92	98	100	121	130	148	164
Minority interest	1	1	3	6	9	9	9	9
Convertibles	0	0	0	0	0	0	0	0
Lease liabilities	0	0	0	0	119	117	123	126
Deferred taxes	4	5	6	6	6	6	6	6
Interest bearing debt	88	42	52	77	99	100	87	67
Non-interest bearing current liabilities	27	42	55	62	80	75	77	79
Other interest-free debt	1	3	3	3	3	3	3	3
Total liabilities	131	185	217	254	437	441	454	455
CASH FLOW, EURm								,
+ EBITDA	14	13	29	34	46	56	66	71
- Net financial items	-3	-2	-1	-1	-4	-4	-5	-5
- Taxes	-1	0	-2	-4	-4	-4	-6	-6
- Increase in Net Working Capital	4	9	7	8	3	3	1	1
+/- Other	-2	-2	-4	-5	-4	-2	-2	-2
= Cash flow from operations	11	18	29	32	38	49	55	59
- Capex	-28	-48	-27	-41	-6	-47	-42	-34
- Acquisitions	0	0	0	0	-79	0	0	0
+ Divestments	0	0	0	0	0	0	0	0
= Free cash flow	-17	-30	2	-9	-48	2	12	25
+/- New issues/buybacks	-29	82	-1	-2	24	0	0	0
- Paid dividend	0	0	0	-3	-3	-2	-4	-7
+/- Other	46	-48	11	24	27	0	-8	-17
Change in cash	0	4	12	10	-1	0	1	1
andinge in cush	O	7	12	10		J	,	į

Health Care/Finland, October 30, 2019 Preview

KEY FIGURES	2015	2016	2017	2018	2019E	2020E	2021E
M-cap	256	380	275	195	238	238	238
Net debt (excl. convertibles)	27	25	40	181	181	172	154
Enterprise value	286	416	325	391	435	425	405
Sales	213	399	424	488	518	534	547
EBITDA	13	29	34	46	56	66	71
EBIT	5	17	20	14	20	34	37
Pre-tax	2	15	19	11	16	29	32
Earnings	2	10	11	5	11	21	23
Equity book value (excl. minorities)	92	98	100	121	130	148	164
Valuation multiples							
EV/sales	1.3	1.0	0.8	0.8	0.8	0.8	0.7
EV/EBITDA	22.5	14.2	9.5	8.5	7.8	6.4	5.7
EV/EBITA	60.8	25.1	16.2	27.1	21.2	12.5	11.1
EV/EBIT	60.8	25.1	16.2	27.1	21.2	12.5	11.1
EV/OCF	16.3	14.5	10.2	10.4	8.9	7.8	6.9
EV/FCFF	-11.0	69.1	-80.9	-9.2	19.4	11.3	8.5
P/FCFE	-8.5	237.3	-28.9	-4.1	113.9	19.3	9.6
P/E	170.5	39.1	25.7	42.4	21.5	11.2	10.2
P/B	2.8	3.9	2.7	1.6	1.8	1.6	1.4
Target EV/EBITDA	0.0	0.0	0.0	0.0	8.3	6.8	6.1
Target EV/EBIT	0.0	0.0	0.0	0.0	22.5	13.3	11.9
Target EV/FCF	0.0	0.0	0.0	0.0	221.3	36.8	17.6
Target P/B	0.0	0.0	0.0	0.0	2.1	1.8	1.7
Target P/E	0.0	0.0	0.0	0.0	24.5	12.8	11.6
Per share measures	0.0	0.0	0.0	0.0	2 1.0	72.0	77.0
Number of shares	20,613	20,613	20,613	22,620	22,620	22,620	22,620
Number of shares (diluted)	20,613	20,613	20,613	22,620	22,620	22,620	22,620
EPS	0.07	0.47	0.52	0.20	0.49	0.94	1.03
Operating cash flow per share	0.85	1.39	1.54	1.66	2.16	2.42	2.59
Free cash flow per share	-1.46	0.08	-0.46	-2.12	0.09	0.54	1.09
Book value per share	4.47	4.74	4.87	5.36	5.75	6.53	7.25
Dividend per share	0.00	0.15	0.16	0.10	0.16	0.31	0.34
Dividend payout ratio, %	0.0	31.9	30.8	49.2	33.0	33.0	33.0
Dividend yield, %	0.0	0.8	1.2	1.2	1.5	3.0	3.2
FCF yield, %	-11.8	0.4	-3.5	-24.6	0.9	5.2	10.4
Efficiency measures	11.0	0.1	0.0	2 1.0	0.0	0.2	
ROE	3.0	10.2	10.8	4.2	8.8	15.3	15.0
ROCE	4.0	11.7	12.2	5.4	5.8	9.4	10.0
Financial ratios	4.0	11.7	12.2				
Financial ratios Inventories as % of sales				0.5	0.5	0.5	0.5
Inventories as % of sales	0.8	0.5	0.5	0.5 8.2	0.5 6.3	0.5 6.3	0.5
Inventories as % of sales Receivables as % of sales			0.5 5.9	0.5 8.2 16.3	0.5 6.3 14.5	0.5 6.3 14.5	0.5 6.3 14.5
Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales	0.8 9.4 19.7	0.5 6.7 13.8	0.5 5.9 14.6	8.2 16.3	6.3 14.5	6.3 14.5	6.3 14.5
Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, %	0.8 9.4 19.7 -9.8	0.5 6.7 13.8 -6.9	0.5 5.9 14.6 -8.4	8.2 16.3 -8.0	6.3 14.5 -8.0	6.3 14.5 -8.0	6.3 14.5 -8.0
Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, %	0.8 9.4 19.7 -9.8 22.3	0.5 6.7 13.8 -6.9 6.8	0.5 5.9 14.6 -8.4 9.7	8.2 16.3 -8.0 1.3	6.3 14.5 -8.0 9.0	6.3 14.5 -8.0 7.9	6.3 14.5 -8.0 6.2
Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), %	0.8 9.4 19.7 -9.8 22.3 22.3	0.5 6.7 13.8 -6.9 6.8 6.8	0.5 5.9 14.6 -8.4 9.7 9.7	8.2 16.3 -8.0 1.3 -15.0	6.3 14.5 -8.0 9.0 9.0	6.3 14.5 -8.0 7.9 7.9	6.3 14.5 -8.0 6.2 6.2
Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), % FCFF/EBITDA	0.8 9.4 19.7 -9.8 22.3 22.3	0.5 6.7 13.8 -6.9 6.8 6.8	0.5 5.9 14.6 -8.4 9.7 9.7 -0.1	8.2 16.3 -8.0 1.3 -15.0 -0.9	6.3 14.5 -8.0 9.0 9.0	6.3 14.5 -8.0 7.9 7.9 0.6	6.3 14.5 -8.0 6.2 6.2 0.7
Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), % FCFF/EBITDA Net debt/EBITDA, book-weighted	0.8 9.4 19.7 -9.8 22.3 22.3 -2.0 2.1	0.5 6.7 13.8 -6.9 6.8 6.8 0.2 0.8	0.5 5.9 14.6 -8.4 9.7 9.7 -0.1	8.2 16.3 -8.0 1.3 -15.0 -0.9 3.9	6.3 14.5 -8.0 9.0 9.0 0.4 3.2	6.3 14.5 -8.0 7.9 7.9 0.6 2.6	6.3 14.5 -8.0 6.2 6.2 0.7 2.2
Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), % FCFF/EBITDA	0.8 9.4 19.7 -9.8 22.3 22.3	0.5 6.7 13.8 -6.9 6.8 6.8	0.5 5.9 14.6 -8.4 9.7 9.7 -0.1	8.2 16.3 -8.0 1.3 -15.0 -0.9	6.3 14.5 -8.0 9.0 9.0	6.3 14.5 -8.0 7.9 7.9 0.6	6.3 14.5 -8.0 6.2 6.2 0.7

Health Care/Finland, October 30, 2019 Preview

OWNERSHIP STRUCTURE	SHARES	EURm	%
Lähitapiola Keskinäinen Vakuutusyhtiö	3,481,641	36.557	15.4%
Mww Yhtiö Oy	2,309,010	24.245	10.2%
Fennia Mutual Insurance Company	1,998,965	20.989	8.8%
Tapiola Keskinäinen Henkivakuutusyhtiö	1,891,385	19.860	8.4%
Elo Pension Company	1,267,161	13.305	5.6%
Niemistö Leena Katriina	703,475	7.386	3.1%
Fondita Nordic Micro Cap	540,000	5.670	2.4%
Ilmarinen Mutual Pension Insurance Company	490,000	5.145	2.2%
Fennia Life Insurance Company Ltd	270,179	2.837	1.2%
Nordea Fennia Fund	258,421	2.713	1.1%
Ten largest	13,210,237	138.707	58%
Residual	9,409,898	98.804	42%
Total	22,620,135	237.511	100%

EARNINGS CALENDAR	
November 05, 2019	Q3 report
OTHER PARTY	
OTHER EVENTS	

COMPANY MISCELLANEOUS	
CEO: Joni Aaltonen	Kehräsaari B, 33200 Tampere
CFO: Tarja Rantala	
IR: Marko Savolainen	

Health Care/Finland, October 30, 2019 Preview

DEFINITIONS

Profit before extraord. items and taxes— income taxes + minority interest Number of shares Dividend for the financial period per share F (Operating cash flow) EBITDA – Net financial items – Taxes – Increase in working capital – Cash NRIs ± Other adjustments F (Free cash flow) Operating cash flow – operative CAPEX – acquisitions + divestments F yield, % Free cash flow Market cap
Dividend for the financial period per share EF (Operating cash flow) EBITDA – Net financial items – Taxes – Increase in working capital – Cash NRIs ± Other adjustments F (Free cash flow) Operating cash flow – operative CAPEX – acquisitions + divestments F yield, % Free cash flow
EF (Operating cash flow) EBITDA – Net financial items – Taxes – Increase in working capital – Cash NRIs ± Other adjustments F (Free cash flow) Operating cash flow – operative CAPEX – acquisitions + divestments F yield, % Free cash flow
EBITDA – Net financial items – Taxes – Increase in working capital – Cash NRIs ± Other adjustments F (Free cash flow) Operating cash flow – operative CAPEX – acquisitions + divestments F yield, % Free cash flow
capital – Cash NRIs ± Other adjustments F (Free cash flow) Operating cash flow – operative CAPEX – acquisitions + divestments F yield, % Free cash flow
Operating cash flow – operative CAPEX – acquisitions + divestments F yield, % Free cash flow
F yield, % Free cash flow
Free cash flow
Free cash flow Market cap
erative CAPEX/sales
Capital expenditure – divestments – acquisitions Sales
t working capital
Current assets – current liabilities
pital employed/Share
Total assets – non-interest bearing debt Number of shares
aring
Net debt Equity
bt/Equity, %
Interest bearing debt Shareholders' equity + minority interest + taxed provisions
uity ratio, %
Shareholders' equity + minority interest + taxed provisions Total assets - interest-free loans
GR, %
Cumulative annual growth rate = Average growth per year

PIHI A JAI INNA

Health Care/Finland, October 30, 2019
Preview

Important Disclosures


Evli Research Partners Plc ("ERP") uses 12-month target prices. Target prices are defined by utilizing analytical techniques based on financial theory including (but not limited to) discounted cash flow analysis and comparative valuation. The selection of valuation methods depends on different circumstances. Target prices may be altered on the basis of new information coming to light in the underlying company or changes in interest rates, changes in foreign exchange rates, other securities prices or market indices or outlook for the aforementioned factors or other factors that may change the conditions of financial markets. Recommendations and changes by analysts are available at <u>Analysts' recommendations and ratings revisions</u>.

Investment recommendations are defined as follows:

Target price compared to share price Recommendation

< -10 % SELL -10 - (+10) % HOLD > 10 % BUY

ERP's investment recommendation of the analyzed company is updated at least 2 timer per year.



The graph above shows the distribution of ERP's recommendations of companies under coverage in 1st of February 2019. If recommendation is not given, it is not mentioned here.

Name(s) of the analyst(s): Rissanen

This research report has been prepared by Evli Research Partners Plc ("ERP" or "Evli Research"). ERP is a subsidiary of Evli Bank Plc. Production of the investment recommendation has been concluded on [30.10.2019, 8:45]. This report has been published on [30.10.2019, 9:20].

None of the analysts contributing to this report, persons under their guardianship or corporations under their control have a position in the shares of the company or related securities.

The date and time for any price of financial instruments mentioned in the recommendation refer to the previous trading day's closing price(s) unless otherwise stated in the report.

Each analyst responsible for the content of this report assures that the expressed views accurately reflect the personal views of each analyst on the covered companies and securities. Each analyst assures that (s)he has not been, nor are or will be, receiving direct or indirect compensation related to the specific recommendations or views contained in this report.

Companies in the Evli Group, affiliates or staff of companies in the Evli Group, may perform services for, solicit business from, hold long or short positions in, or otherwise be interested in the investments (including derivatives) of any company mentioned in the publication or report.

Neither ERP nor any company within the Evli Group have managed or co-managed a public offering of the company's securities during the last 12 months prior to, received compensation for investment banking services from the company during the last 12 months prior to the publication of the research report.

ERP has signed an agreement with the issuer of the financial instruments mentioned in the recommendation, which includes production of research reports. This assignment has a limited economic and financial impact on ERP and/or EVIi. Under the assignment ERP performs services including, but not limited to, arranging investor meetings or –events, investor relations communication advisory and production of research material.

ERP or another company within the Evli Group does not have an agreement with the company to perform market making or liquidity providing services. months prior to, received compensation for investment banking services from the company during the last 12 months prior to the publication of the. For the prevention and avoidance of conflicts of interests with respect to this report, there is an information barrier (Chinese wall) between Investment

EVLI EQUITY RESEARCH

PIHLAJALINNA

Health Care/Finland, October 30, 2019
Preview

Research and Corporate Finance units concerning unpublished investment banking services to the company. The remuneration of the analyst(s) is not tied directly or indirectly to investment banking transactions or other services performed by Evli Bank Plc or any company within Evli Group.

This report has not been disclosed to the company prior to its dissemination.

This report is provided and intended for informational purposes only and may not be used or considered under any circumstances as an offer to sell or buy any securities or as advice to trade any securities.

This report is based on sources ERP considers to be correct and reliable. The sources include information providers Reuters and Bloomberg, stock-exchange releases from the companies and other company news, Statistics Finland and articles in newspapers and magazines. However, ERP does not guarantee the materialization, correctness, accuracy or completeness of the information, opinions, estimates or forecasts expressed or implied in the report. In addition, circumstantial changes may have an influence on opinions and estimates presented in this report. The opinions and estimates presented are valid at the moment of their publication and they can be changed without a separate announcement. Neither ERP nor any company within the Evli Group are responsible for amending, correcting or updating any information, opinions or estimates contained in this report. Neither ERP nor any company within the Evli Group will compensate any direct or consequential loss caused by or derived from the use of the information represented in this publication.

All information published in this report is for the original recipient's private and internal use only. ERP reserves all rights to the report. No part of this publication may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in any retrieval system of any nature, without the written permission of ERP.

This report or its copy may not be published or distributed in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore or South Africa. The publication or distribution of this report in certain other jurisdictions may also be restricted by law. Persons into whose possession this report comes are required to inform themselves about and to observe any such restrictions.

Evli Bank Plc is not registered as a broker-dealer with the U. S. Securities and Exchange Commission ("SEC"), and it and its analysts are not subject to SEC rules on securities analysts' certification as to the currency of their views reflected in the research report. Evli Bank is not a member of the Financial Industry Regulatory Authority ("FINRA"). It and its securities analysts are not subject to FINRA's rules on Communications with the Public and Research Analysts and Research Reports and the attendant requirements for fairness, balance and disclosure of potential conflicts of interest. This research report is only being offered in U.S. by Auerbach Grayson & Company, LLC (Auerbach Grayson) to Major U.S. Institutional Investors and is not available to, and should not be used by, any U.S. person or entity that is not a Major U.S. Institutional Investor. Auerbach Grayson is a broker-dealer registered with the U.S. Securities and Exchange Commission and is a member of the FINRA. U.S. entities seeking more information about any of the issuers or securities discussed in this report should contact Auerbach Grayson. The securities of non-U.S. issuers may not be registered with or subject to SEC reporting and other requirements.

ERP is not a supervised entity but its parent company Evli Bank Plc is supervised by the Finnish Financial Supervision Authority.

Health Care/Finland, October 30, 2019 Preview

Contact information SALES, TRADING AND RESEARCH

Equity Sales		Trading		ETFs and Derivatives	
Ari Laine Lauri Ahokanto Niclas Henelius	+358 9 4766 9115 +358 9 4766 9117 +358 9 4766 9116	Lauri Vehkaluoto (Head) Pasi Väisänen Antti Kässi Miika Ronkanen	+358 9 4766 9120 +358 9 4766 9120 +358 9 4766 9120 +358 9 4766 9120	Joachim Dannberg Kimmo Lilja	+358 9 4766 9123 +358 9 4766 9130
Structured Investments		Equity Research			
Heikki Savijoki Aki Lakkisto	+358 9 4766 9726 +358 9 4766 9123	Jonas Forslund Joonas Ilvonen Jerker Salokivi Anna-Liisa Rissanen	+358 9 4766 9314 +358 44 430 9071 +358 9 4766 9149 +358 40 157 9919		
Evli Investment Solutions					
Johannes Asuja Markku Reinikainen	+358 9 4766 9205 +358 9 4766 9669				



EVLI BANK PLC
Aleksanterinkatu 19 A
P.O. Box 1081
FIN-00101 Helsinki, FINLAND
Phone +358 9 476 690
Fax +358 9 634 382
Internet www.evli.com
E-mail firstname.lastname@evli.com

EVLI BANK PLC, STOCKHOLMSFILIAL Regeringsgatan 67 P.O. Box 16354 SE-103 26 Stockholm Sverige stockholm@evli.com Tel +46 (0)8 407 8000 Fax +46 (0)8 407 8001